Company intelligence / Profile preview

JAGUAHR Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

JAGUAHR Therapeutics is developing novel small-molecule aryl hydrocarbon receptor antagonists as immuno-oncology therapeutics for solid tumours, with current development at the preclinical stage and an earlier plan to file an IND around 2022.[1][2]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

AhR antagonist program

Pre-clinical

Indications: Cancer

Partnerships

ASLAN PharmaceuticalsBukwang Pharmaceutical

Beyond the preview

Go deeper on JAGUAHR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAGUAHR Therapeutics.

Explore the full profile